June 2023 ACIP Meeting - Polio

CDC
258 followers
Feb 4, 2025
Introduction; Recommendations for Adult Polio Vaccination
This video can also be viewed at
https://www.cdc.gov/vaccines/videos/low-res/ACIPJune2023/ACIP-2_PolioVaccine_06-21-2023-Day1_LowRes.mp4
I just wanted to reconvene the acip
session thanks everyone for giving us a
one minute break um and we're going to
start with Dr Brooks uh who will provide
an he's chair of our acip polio vaccine
workg group he will provide an
introduction and overview of today's
session all right all right thank you
very much um chairman Lee so polio work
group was formed about a year ago maybe
a year and a half ago um for reasons of
which you all are aware and the posted
here there terms of
reference policy topics under
consideration so first whether more
specific guidelines of adult vaccination
including the use of adult booster doses
can be provided in the context of
circulating polio virus which is
obviously the key issue whether adults
or imuno compromised should be
recommended an additional adult booster
of a poo vaccine polio containing
vaccine whether fractional doses of ipv
as pre-qualified by the World Health
Organization should meet polio vaccine
vaccination requirements including for
people immigrating to the US and
consider criteria on Which novel oral
polio vaccine type 2 might be used in
areas without breaks or persistent
circulation of the polio virus so at
this point we will be uh discussing and
evaluating and voting on number one uh
term of reference so with that next
slide I turn it over to Dr kid our
fearless leader of the work
group thank you Dr
Brooks so next slide good afternoon
everyone um today I'll be presenting on
behalf of the polio vaccination workg
group there are two main objectives for
today's presentation first I'll
summarize the polio workg group
deliberations on adult polio vaccination
specifically for recommendations for
unvaccinated and incomp completely
vaccinated adults and recommendations
for booster doses of ipv and then I'll
present the work group's proposed
language for an AC acip vote later this
afternoon next
slide I'll be presenting the work group
deliberations using the acip evidence to
recommendations framework that you're
familiar with and according to the ETR
domains listed here next
slide as background the most recent acip
statement on adult polio vaccination was
published in 2000 and it contains some
ambiguous and outdated language the 2000
statement states that vaccination is
recommended for certain adults who are
at greater risk of for exposure to polio
viruses than the general
population unvaccinated adults who are
at increased risk of exposure should
receive a primary vaccination series
with ipv and adults who have had a
primary series of oral polio vaccine or
ipv
and who are at increased risk of
exposure can receive another dose of
ipv next
slide multiple problems and questions
about the recommendations came to light
last year when the New York po paralytic
polio case was
identified first the 2000 statement
focuses almost exclusively on adults at
increased risk of poliovirus
exposure and it was unclear how
increased risk should be defined in the
setting of circulating vaccine derived
polio viruses in the United States in
addition there was no clear guidance for
unvaccinated adults who were not known
to be at increased risk of exposure and
there was uncertainty about vaccinated
adults and when and if a booster was
advised next
slide so the first policy question the
work group addressed was should
completion of a primary polio
vaccination series with ipv be
recommended for unvaccinated and
incompletely vaccinated adults in the US
to be more precise the population of
Interest was unvaccinated and
incompletely vaccinated us adults aged
18 or
over the intervention is completion of a
primary vaccination series with ipv the
comparison group is no vaccination or
partial series completion and the most
important outcomes of Interest were
prevention of paralytic polio serologic
immunity to polio viruses types 1 2 and
three serious Adverse Events following
vaccination and then also indirect
effects such as transmission and impact
on Health
Systems next
slide and just to keep in mind the
current definition of fully vaccinated
um an adult is considered fully
vaccinated against polio if they
received a primary series of at least
three doses of trivalent opv or ipv in
any combination administered at least
four weeks apart and the last dose in
the series was given on or after the
fourth birthday and the last dose in the
series was given at least six month
months after the previous dose next
slide as this group knows poliovirus
infection can cause poliomyelitis and
lifelong paralysis but paralytic disease
occurs in fewer than 1% of infections
with the exact frequency varying by
serotype and most poliovirus infections
are
asymptomatic next
Slide the incidence of paralytic polio
decreased rapidly in the United States
after introd C of the sulk inactivated
polio vaccine quickly followed by the
Sabin oral polio vaccine the Sabin oral
vaccine was used for routine childhood
immunization in the US for decades and
in 1997 an enhanced potency ipv was
introduced as part of a sequential
schedule with ipv with
opv in 2000 the US removed the US moved
to an ipv only schedule and ipv has been
the only polio vaccine recommended in
the US since that
time next
slide wild polio virus type 1 and
vaccine dve polio viruses are still
circulating in certain parts of the
world this figure shows the distribution
of the almost 700 paralytic polio cases
that have been identified in the last 12
months of note environmental detections
for instance from Wastewater are not
shown in this
figure next slide
and then as you are aware a case of
paralytic polio caused by vaccine
derived polio virus type 2 was confirmed
in an unvaccinated young adult from
Rockland County New York in July last
year genetic sequencing has indicated a
linkage to polio viruses collected in
Wastewater in Israel the United Kingdom
and
Canada and of note Rockland County has
reported overall low vaccine coverage
for over 20 years now in the summer of
2022 um just 60% of children under age 2
had received three doses of ipv but zip
code level coverage was as low as 37% in
some
areas fortunately no additional
paralytic cases have been
identified next
slide polio virus related to the case
was detected in Wastewater and several
other New York um was in several other
New York counties and New York
City respective testing detected polio
virus in the area as early as April 2022
indicating circulation and asymptomatic
infections in the area at least since
that
time related virus continued to
consistently be detected in Wastewater
until the beginning of November last
year only two samples have been positive
for polio virus since November 1st with
the most recent um being collected on
February 22nd in Rockland County samples
collected in the last 15 weeks have all
been negative next
slide this figure shows the pattern of
Wastewater detections in each affected
County by week with poliovirus
detections depicted in red and negative
poliovirus samples in blue and to
reiterate there was just one paralytic
polio case identified but the presence
of that case and the pattern of
Wastewater detections indicate that
there were there were likely at least
one to 2,000 mostly asymptomatic
infections in the area
next
slide circulating polio virus poses a
risk of paralytic polio to those who who
do not have immunity and in the United
States most people are protected from
paralytic polio because they've been
vaccinated National sulk ipv vaccination
campaigns in the late 1950s targeted all
persons up to the age of 40
years this table shows National
household survey data for sulk ipv
vaccination coverage by September 1961
by age and race in general campaign
coverage was highest among children who
are aged 5 to 14 years in 1961 so this
would be birth years 1947 to
1956 also of note estimates of coverage
were higher among whites than non-whites
in all age
groups next
slide in comparison to children and
Adolescence coverage was lower in adults
age 20 and older um and not many adults
40 or over were vaccinated in the
campaigns next
slide after that particular household
survey subsequent surveys focused on
coverage among preschool aged
children this figure shows data from
three different National surveys for
three dose polio vaccination coverage
among children I want to note that these
are different surveys which use
different methodologies and have
different limitations in particular the
first survey USIS s was based on
Parental recall and is thought to
undermate underestimate actual coverage
by as much as 20% when it was compared
to actual vaccination records in
contrast the national immunization
survey or NIS data come from actual vac
vaccination
records so while coverage levels here
especially in the um 70s and 80s might
be caused for concern if you go to the
next
slide um it's interesting to contrast
those coverage data with ser surveys
that indicate that a large majority of
Americans have protective antibodies to
polio
virus in this inhan survey that was
conducted in 2009 to 2010 Sero
prevalence varied by poliovirus serotype
but was high in all the age groups
studied seral prevalence for type 3 was
consistently the lowest but remained
High even in the oldest age group Next
slide of note there were some small
differences in Sero positivity by race
ethnicity group but none of these were
statistically significant among the
younger age
groups next
slide among older adults differences by
race ethnicity were generally not
statistically significant either with a
few exceptions where Mexican-American
adults had slightly lower Ser prevalence
of type 2 antibodies compared to
non-hispanic blacks in the 20 to 39e age
group and compared to non-hispanic
whites in the 40 to 49 year age group
they also had lower levels of type three
antibodies compared to non-hispanic
whites in the 40 to 49e age
group unfortunately there are no Sero
prevalence data for older age groups by
race
ethnicity so next
slide so to summarize the problem the US
remains at risk of polio virus
importations as long as there's ongoing
transmission of polio virus globally
data indicate that most us adults have
serologic immunity to polio viruses type
1 2 and 3
however unvaccinated and incompletely
vaccinated adults remain susceptible to
paralytic polio if exposed to polio
virus next
slide so in response to the question for
the ETR domain is paralytic polio a
problem of Public Health importance the
work group agreed that yes paralytic
polio is a problem of Public Health
importance next
Slide the effectiveness of enhanced
poent ipv has been established the
presence of detectable neutralizing
antibod is an accepted corate of
protection against paralytic disease
however immunity against paralytic
disease can be present even in the
absence of detectable
antibodies studies of the serologic
immunogenicity among infants and
children show that 70 to 100% are
seropositive after two ipv doses and 88
to 100% are seropositive after three
doses there are limited Deb on the
vaccine Effectiveness against um against
paralytic polio but estimates range from
36 to 89% for one dose and 89 to 98% for
two
doses however because this is a routine
childhood vaccine there's aity of data
for PR previously unvaccinated adults
who receive a PRI primary
series next
slide in addition to serologic immunity
which protects against severe disease
and paralysis it's also important to
consider mucosal immunity and the
potential effect of ipv on
transmission ipv does not decrease the
proportion of people who will shed polio
virus when exposed multiple Studies have
shown that there is no significant
difference between ipv and unvaccinated
individuals in terms of the odds of
shedding however SE however several
studies indicate that ipv may reduce the
quantity and perhaps duration of
shedding although a recent modeling
study indic indicated no impact of
ipv there are fewer data on naso ferial
immunity following ipv but data from two
studies suggest that rates of n naso
fenial shedding are similar and low 0 to
4% among both opv and ipv
vaccines next
slide in terms of safety the safety of
ipv is also well established and ipv is
well
tolerated local reactions at the
injection site were reported during
clinical trials and up to a third
reported aemma induration or tenderness
at the injection
site combining ipv with other vaccines
has not been associated with increased
frequency or severity of reported
adverse reactions compared to with the
when the other vaccines are administered
alone and no serious Adverse Events have
been causally associated with the use of
the current formulation of
ipv next slide
in a paper that looked at 2000 to 2012
data from the vaccine adverse event
reporting system during a period when
more than 250 million ipv doses were
distributed during
20122
41792 adverse event reports were
submitted for ipv containing
vaccines most of these were non- serious
and 95% were among persons less than 7
years of age most events were associated
with ipv that was co-administered with
other vaccines and Standalone ipv
accounted for just 0.5% of
reports it is important to remember that
vs is a passive reporting system and
can't assess causal associations between
vaccination and Adverse Events however
the lack of signal and vs after Decades
of ipv use is
reassuring next
slide therefore for the ETR domain of
benefits and harms the work group
interpretation was that if you take take
into account both individual and
population level effects the desirable
anticipated effects of completing a
polio vaccination series are large next
Slide the undesirable anticipated
effects are minimal next slide and the
anticipated benefits of completing a
primary polio vaccination series
outweigh the anticipated
harms next
slide when thinking about population
values there was an anenberg science
knowledge survey conducted in October
last year that included questions about
polio so we actually have some data on
what the general public thinks about
polio
recently in this survey 59% of people
said that it would be extremely bad to
have polio and an additional 26% said it
would be very bad to have polio this was
a higher proportion of of the population
than for other diseases Sur diseases
surveyed including long covid monkey pox
or impx or measles so there's evidence
that the General Public values polio
prevention at least at the individual
level in addition 85% said they were
likely to recommend that an eligible
person in their household get vaccinated
with the polio vaccine indicating
relatively High accept acceptability of
the vaccine among the general
public next
slide however when thinking about the
values of the specific population in
question which is unvaccinated or
incompletely vaccinated adults it's
likely that this is a heter genius group
that consists both of persons whose
family chose for them to not be
vaccinated as children and persons who
missed opportunities to be vaccinated as
children and there's a lack of data on
how these populations currently perceive
their risk of paralytic polio and how
they perceive the anticipated positive
versus negative effects of polio
vaccination next
slide additional acceptability
considerations include of course the
context of global polio eradication
efforts and that the prevention of
paralytic polio has been a public health
priority for decades but in practice
there are currently many competing
priorities for clinicians and local
Health local public health departments
and uncertainty about who is eligible
for vaccination and outside of an
outbreak setting uncertainty about the
true level of risk to adults in the US
could also undermine
acceptability next
slide so in response uh to the ET
question of whether the Target
population of unvaccinated or
incompletely vaccinated adults feel that
the desirable effects of vaccination are
large relative to the undesirable
effects the work group thought that it
likely varies because of the
heterogeneity of this group Next
slide and as reflected on the previous
Slide the work group felt that there is
probably important uncertainty or
variability in the values of the target
population next
slide in contrast for acceptability of
key stakeholders overall the work group
felt that providing a primary series to
unvaccinated or incompletely vaccinated
adult was probably acceptable to key
stakeholders and then moving on to
feasibility uh discussions in terms of
feasibility and potential supply and
demand there currently is just one US
licensed manufacturer of Standalone
ipv um however uh and there currently
are three us licensed manufacturers of
combination vaccines that include IP
however these combination vaccines are
currently not indicated for
adults the potential demand for ipv is
difficult to quantify we don't have data
on the number of adults who know they
are unvaccinated or incompletely
vaccinated so it's difficult difficult
to quantify potential demand next
slide in practice we can learn from New
York's experience last summer New York
State and New York City did not
experience any significant ipv supply
issues isues despite identification of a
polio case persistent Wastewater
detections in the area National mediate
attention and calls in a coned e
concerted effort by the health
department to reach um to vaccinate
unvaccinated persons including
adults next
slide other resource and feasibility
considerations include issues with
access Adult Medicine offices typically
don't stock ipv so access to vaccination
sites that do stock I PV could be a
barrier to
implementation also there are concerns
about potential effects on health
systems and their vaccine screening and
patient recall algorithms but it was
felt that these concerns could be
mitigated with clear guidance for who is
eligible for vaccination with these
recommendations and then finally the
work group talked at length about the
feasibility of implementing risk-based
recommendation risk-based
recommendations particularly if risk of
exposure in the population changes over
time and and I'll say more about this
topic in a few
slides next slide but overall the work
group felt the vaccination of adults who
are known or suspected to be
unvaccinated or incompletely vaccinated
was probably or was a reasonable and
efficient allocation of
resources next slide they also felt that
it was probably feasible to implement
and next
slide
sorry Pap probably eible to implement
and thought next uh for the next domain
of equity considerations um we know that
there are different rates of childhood
vaccination and poliovirus Immunity in
different
communities and that having an
opportunity to receive catch-up polio
vaccination as an adult likely um
increases
Equity there are no known differences in
vaccine Effectiveness among
immunocompetent persons in the US
setting and finally assuring Equitable
access to vaccination sites with with
ipv will be an important consideration
for
implementation next
slide so overall the work group felt
that providing polio vaccination for
adults known or suspected to be
unvaccinated or incompletely vaccinated
would probably increase
Equity next
slide for the overall balance of
consequences taking into account all of
the ETR domains just presented the workg
group considered two different
populations of unvaccinated adults for
unvaccinated and incompletely vaccinated
ated adults known to be at increased
risk of poliovirus exposure the work
group's judgment was that the desirable
consequences clearly um outweigh
undesirable consequences in both
settings next
slide for unvaccinated or incompletely
vaccinated incompletely vaccinated
adults who are not specifically known to
be at increased risk of poliovirus
exposure the work group's judgment was
that desirable consequences probably
outweigh undesirable conse consquences
in most
settings next
slide most of the work group
deliberations were focused on whether
the recommendations for unvaccinated
adults should be a risk-based
recommendation or a uniform
recommendation for all unvaccinated
adults currently situations that are
considered to put adults at increased
risk of poliovirus exposure include
International Travelers laboratory and
healthcare workers and healthcare
workers or other
caregivers in addition unvaccinated or
incompletely vaccinated adults whose
children will be receiving an oral polio
vaccine and unvaccinated adults or
incompletely vaccinated adults who are
living or working in a community where
polio virus is circulating are
considered to be at increased risk of
exposure and vaccine is
recommended next
slide it became clear to the workg group
that most of these situations POS risk
at the individual level and there would
be an opportunity to anticipate the risk
and vaccinate prior to the potential
exposure next
slide but this last situation for
unvaccinated and incompletely vaccinated
adults in a community where polio virus
was circulating was a little bit
different this situation affects an
entire population and the community is
already at increased risk at the time
the risk is
recognized this means there would
potentially be missed opportunities for
vaccination prior to exposure if the
recommendation remains solely a
risk-based
recommendation
next
slide additional challenges with the
current risk-based recommendation came
to light in 2022 as CDC and New York
city and state health departments
received numerous questions about which
adults were at increased risk of
exposure for instance in which of these
counties with Wastewater detections or
adjacent to Wastewater detections are
unvaccinated adults considered at
increased risk of exposure our counties
with a single Wastewater detection of
polio virus considered to be at
increased risk of
exposure when are unvaccinated adults in
these counties no longer at increased
risk of exposure and are unvaccinated
adults traveling to these counties at
increased risk of
exposure as Wastewater surveillance
becomes more common it's possible that
other jurisdictions might experience
sporadic detections of polio virus in
their Wastewater and these are the types
of challenges that come up when trying
to implement a risk-based
recommendation next
slide with these s in mind the pros of a
uniform recommendation are that it
allows unvaccinated adults and their
Healthcare Providers to take advantage
of opportunities to get vaccinated
before they are at increased risk of
exposure it also brings adult polio
vaccination policy closer in line with
other routine childood vaccines such as
MMR and vericella vaccines and in
addition it's a less complicated policy
to to communicate and understand and
Implement in that the recommendation
doesn't change based on the latest
Wastewater data
next
Slide the cons are that most adults in
the United States still have a low risk
of polio virus exposure and paralytic
polio and most adults received primary
polio vaccination their primary polio
vaccination series as
children the other con is that demand
for ipv could potentially exceed Supply
particularly if a large number of adults
without documentation of poo vaccination
status were to assume that they were not
vaccinated however again this issue the
gr group felt that this issue could be
mitigated by providing guidance for this
group in the clinical
considerations next
slide ultimately the majority of the
work group supported a uniform
recommendation however a substantial
minority favor the current risk-based
recommendation with the addition of
language specifically addressing
unvaccinated adults who are not known to
be at increased risk of
exposure so the majority proposed
language is that adults who are known or
suspected to be un un vaccinated or
incompletely vaccinated against polio
should complete a primary vaccination
series with
ipv next
slide this language has to be taken in
the context of who is um or who should
be considered unvaccinated in the
clinical considerations so the following
is important context that will be
included in the clinical considerations
in general unless there are specific
reasons to believe they were not
vaccinated most adults who were born and
raised in the United States can assume
they were vaccinated against polio as
children polio vaccination has been part
of the routine childhood immunization
schedule for decades and is still part
of the routine childhood immunization
schedule adults who received any
childhood vaccines only almost certainly
were vaccinated for
polio so next
slide now I'm going to move on to the
second policy
question next
Slide the second policy question
addressed by the workg group was should
a booster ipv dose be recommended for
adults at increased risk of poliovirus
exposure who have previously completed a
primary polio vaccination
series um again the specific population
being considered is us adults aged 18
years or over who are at increased risk
of polio virus exposure and who have
also completed a primary polio
vaccination series with trivalent opv
ipv or a combination of both the
intervention is a booster dose of ipv
and the comparison group is adults who
completed a primary series but did not
receive a booster dose again the main
outcomes of Interest were prevention of
paralytic polio serologic immunity to
polio polio virus types 1 two and three
serious Adverse Events following
vaccination and then also indirect
effects such as Community transmission
and impact on Health
Systems next
Slide the current recommendation
regarding adult boosters is that adults
who have had a primary series of opv or
IP ipv and who are at increased risk of
exposure to polio virus can receive
another dose of ipv available data do
not indicate the need for more than a
single lifetime booster dose with ipv
for
adults this has been a long-standing
recommendation since trivalent opv was
used in routine immunization however the
actual need for supplement for a
supplementary dose has not been
established but it has been thought that
there is value in assuring protection
against infection with wild poo viruses
when exposure can reasonably be
expected um of note there were at least
two reported cases of paralytic polio
and an adult Travelers who had completed
a primary series with either sulk ipv or
trivalent opv however further details on
these cases are not available and it's
unknown whether a booster dose would
have prevented these
cases next
slide so this 2000 guidance was
complicated in 2014 when CDC issued
interim guidance in response to new wh
polio International Health regulations
emergency committee temporary
recommendations these who
recommendations apply were for travelers
who were departing countries with
poliovirus circulation in order to
prevent
exportation and they applied to
Residents and also Travelers who were
staying in the country for more than
four
weeks if implemented by a country proof
of polio vaccination within the last 12
months could be required prior to
leaving the country and this uh
recommendation or a similar
recommendation is still included the
most recent polio IH
statement so in response to this new who
recommendation in 2014 which differed
from acip recommendations CDC published
interim guidance in 2014 that stated as
a precaution persons aged 18 years or
older who are traveling to areas where
there has
been wild polio virus circulation in the
last 12 months and who have received a
routine series
with either ipv or opv in childhood
should receive another dose of ipv
before
departure next
slide it's unclear whether previously
vaccinated adults need an ipv booster
for protection shown here again are the
results of the inhan Sero survey showing
that the Sero prevalence of neutralizing
antibodies is high for all three
stereotypes and in all age groups
studied next slide
there are no data on the comparative
vaccine effectiveness of a primary
series plus booster compared to a
primary series alone but serologic
studies in adults with heterogeneous
pre-booster vaccination histories and
heterogeneous copositivity have shown
that 98 to 100% are seropositive one
month after receiving an ipv containing
booster one study also followed up trial
participants 10 years later and 98 to
100 98 to 100% were still Ser positive
at that
time next
Slide the safety of ipv was previously
described in this presentation but I'll
point out again that combining ipv with
other vaccines has not been associated
with increased frequency or severity of
reported adverse reactions compared with
when other vaccines are administered
alone and no severe Adverse Events have
been causally associated with the
current formulation of
ipv next
slide so for the ETR domain of benefits
and harms the workg group determined
that for adults at increased risk of
exposure the desirable anticipated
effects of receiving an IP ipv booster
were small to moderate and next Slide
the undesirable effects were minimal and
next Slide the anticipated benefits
outweigh the anticipated
harms next
slide considering Target population
values I'm showing you again the results
of that anenberg survey conducted last
year that shows the majority of adults
surveyed thought that having polio would
be extremely bad or very bad and that
85% said that they were likely to
recommend that someone in their
household get vaccinated against polio
if they were eligible next
slide so the work group thought that the
target population meaning previously
vaccinated adults who were at increased
risk of exposure probably felt that the
desirable effects of a booster were
large compared to the undesirable effect
however this was split with a
significant portion of the work group
also saying that we don't know based on
the limited data
available next
slide but the work group thought there
probably wasn't or wasn't important
uncertainty or variability in terms of
Target population
values next
slide when considering acceptability
feasibility and resources for ipv Boost
ipv boosters the workg group noted that
the current recommendation that adults
who have had a prim primary series of
opv or ipv and who are at increased risk
of exposure to polio virus can receive
another dose of ipv that this
recommendation is long-standing and is
generally considered acceptable accepted
and
feasible however if the at increased
risk of exposure group were to be
expanded for instance to include
previously vaccinated adults in certain
us us areas with poliovirus circulation
feasibility might be affected in the
future and again the experience of new
yor State and New York City in 2022 is
helpful in that even in the context of a
polio case and media attention ipv with
Supply um was not a a significant
issue next
slide so the work group agreed that
providing a booster ipv dose to adults
at increased risk of exposure probably
was or was acceptable to key
stakeholders and next slide that it
probably was a reasonable and efficient
allocation of resources and next slide
and that it was also probably um also
probably was or was feasible to
implement next slide finally to address
Equity ET domain there are no known
differences in response to a primary
series or need for a booster by
socioeconomic group in the US setting
and no groups or settings are known to
be disadvantaged by the current
recommendation however the work group
thought there that there is a potential
for increased Equity by boosting
immunity in persons at increased risk of
Expos exposure especially persons with
potential occupational exposures to
polio
virus next
slide so on that basis overall the workg
group thought that boosters for those at
increased risk of exposure probably
increased
Equity next slide for the overall workg
group judgment taking into account all
of the ETR domains the workg group
thought that the desirable consequences
of an ipv booster probably outweigh the
undesirable consequences in most
settings for previously vaccinated
adults who are at increased risk of
poliovirus exposure next slide so the
majority of the workg group agree with
the current acip recommendation for
adult boosters and we're asking for a
vote to reaffirm this language this
recommendation is risk-based and based
on shared clinical decision-making and
the proposed language includes some
slight edits to mod modernize the
language compared to the 2000 statement
the proposed language is adults who have
received a primary series of trivalent
opv or ipv in any combination and who
are at increased risk of poliovirus
exposure may receive another dose of ipv
available data do not indicate the need
for more than a single lifetime booster
dose with ipv for
adults next
slide for the clinical considerations
I'll just repeating the situations that
put adults at increased risk of polio
virus exposure or examples that are
given um these examples include
Travelers who are going to countries
where polio is epidemic or endemic
laboratory and healthcare workers who
handle specimens that might contain
polio viruses healthcare workers or
other caregivers who have close contact
with a person who could be infected with
polio
virus next
slide so this concludes my presentation
and I'd like to thank the polio work
group members for participating in these
discussions and providing their valuable
input next slide thank
you thank you Dr kid that was such a
clear presentation really appre
appreciate it um this presentation is
now open for questions and
discussion Dr
peing so would you put the first um
language up for the first vote there was
two reaffirming and then the first one
so first of all I want to say while
you're doing that I want to say thank
you Dr kid for a very clear and well
organized um presentation it was
outstanding and um I think one of the
points that you made is really important
that for every one case of paralytic
polio you probably have 999 asymptomatic
cases and so um that ratio is really
important um so can we get the
language um do you need me to say the
slide
number Stephanie I'm sorry my computer
restarted so I'm pulling up my SL deck
right now so I can give you a slide
number
okay thank
you um that is exactly it so I would
like to make a motion to accept the um
wording on the slide thank
you thank you Dr paling do I have a
second um Dr talbet I second
thank you it's been moved and seconded
to accept the proposed language for
unvaccinated and incompletely vaccinated
adults as written on the slide
here any additional
comments um Dr cotton just very briefly
it looks as though there really isn't
much information to inform
decision-making in with imuno
compromised patients and it doesn't look
as though there's any um consideration
for them likely due to the lack of data
but I would just highlight that three an
estimated 3% of the US population is
immune compromised and we should um
consider them and their risk especially
where they may be traveling after the
onset of immune suppression um and so
they may well remain vulnerable and
could actually be a major public health
situation in that they may shed virus
for a longer period of time Etc so thank
you thank you Dr
Sanchez
that was a very nice uh presentation and
I agree with the proposed language I
just wanted to comment on the clinical
considerations you kind of brought this
up already but I think um indiv
individuals who are going to be taking
care of children who've been recently
vaccinated with oral polio um maybe
another risk group and you said you
mentioned International
adops um you you put um healthcare
workers or other caregivers who could be
infected with polio but if they've
recently received um oral Polio I don't
know if that's maybe another
consideration currently the current
guidance is um that unvaccinated persons
who would be might be in contact with
shed opv um would be considered high-
risk but the that a booster would not
necessarily be indicated in that
situation no I agree okay you approve
okay Dr lar um I take care of a large
number of partially vaccinated or
unvaccinated patients so this is
actually very relevant for my practice
and I appreciate the work group working
on this I also want to comment that it
is in my experience that when people
decide to vaccinate polio is almost
always the first vaccine they choose to
do and so I think you're quite right
that if you've ever had any childhood
vaccines you probably got polio because
it's such a scary disease and such a
boring safe vaccine so I think that's
very um reasonable approach that if
you've ever had any childhood vaccines
you probably got
polio thank you and for the record we
don't think vaccines are
boring um Dr paling all right would you
mind pulling up the second vote
language okay um and so so um as I
understand this Dr kid this is a
reaffirming using more modern language
um the recommendation that
exist correct and it's also uh just
clarifying where what acip recommends in
the context of the um the
2014 the The Who recommendations and
wording that has been in effect since
2014 okay fantastic um I would like to
make a motion to accept um this
recommendation as worded thank you Dr
paling do we have a motion on the table
would anybody like to
second
dras I would like to second that motion
thank you it's been moved and seconded
that we accept the current wording on
the slide for vote number two for polio
vaccines any
other oh Dr cotton I would like to to
just comment that we don't know that a
single dose a single lifetime booster
dose with ipv for adults is appropriate
for immune compromised that data is not
known I I would not amend this but um we
don't know that to be true it often is
not true for immune
compromised any other questions or
comments oh I see um Dr Dr
Jani
thank you uh representing uh Association
of state and territorial Health
officials uh so when in the next slide
on this where you uh identified what
would be identified as potential risk of
poliovirus exposure uh there is no
reference specifically to the type of
incident we had most recently in terms
of vaccine derived um strains and so I
wanted to know if there was any sort of
thought on clinical considerations that
could help providers in communities
where they may have a vaccinated people
particularly older adults this came up
for a lot of people um in terms of
assessing risk for them uh given that
they probably were vaccinated a very
long time ago thank
you yeah that's a um challenging
question and something the work group um
has brought up and
discussed uh first of all this this
applies to all polio viruses so whether
it's a wild strain or vaccine derive um
polio virus so just to clarify that uh
in terms of recommendations for if there
is a case of polio detected in in the
United States or Wastewater detections
um I think it's challenging to give uh
standard or Universal recommendations at
this point I think we would have to work
with the health department based on uh
the pattern of detections and um the the
type of virus whe whether it was Sav and
like or had enough um changes that it
was vaccine derived um to to make a Call
of recommendations for boosters at this
time I think the nice part the benefit
of moving to a uniform recommendation
for unvaccinated adults is that there's
a clear uniform recommendation for
unvaccinated adults there's Clarity of
that we don't have to split hairs about
what is increased risk for those people
or not um go ahead and get those
vaccinated but in terms of when boosters
might be recommended um is I think uh
something we'll have to work with health
departments and and what happens uh what
that's what the specific situation
entails uh Dr
good just a a point of clarification is
that in the 2000 recommendations there
were three statements so these two
statements would replace those three
statements can you go to the previous
slide
please
um there's two statements in the 2000 uh
the second sentence is identical or
virtually identical the main change in
the first statement is it's replacing a
can with a May and I think it describes
um uh primary Series in more detail
primary series of of trivalent opv or
ipv in any
combination
I don't see any other hands raised in
the room or on the chat so oh is it did
I miss ah Dr paling I always miss this
side yeah I do want to just clarify that
in the United States we give ipv as a
childhood vaccine so if there's an
exposure to opv there should be travel
associated with that because we are not
giving and I want to make sure that I'm
speaking correctly Dr kid you're correct
that um yes ipv is the only polio
vaccine uh approved in the US since
2000 thank you so with that we will
close this session thank you Dr Brooks
and Dr kid for catching us up and
allowing us to be on time we really
appreciate it we'll take a 15minute
break and return at 30 minutes after the
hour for influenza thanks to our
speakers
